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Abstract 
Background: Hereditary angioedema with C1 inhibitor deficiency (C1-INH-HAE) is characterized by recurrent swell-
ing in subcutaneous or submucosal tissues. Symptoms often begin by age 5–11 years and worsen during puberty, 
but attacks can occur at any age and recur throughout life. Disease course in elderly patients is rarely reported.
Methods: The Icatibant Outcome Survey (IOS) is an observational study evaluating the safety, tolerability, and 
efficacy of icatibant. We conducted descriptive analyses in younger (age < 65 years) versus elderly patients 
(age ≥ 65 years). Here, we report patient characteristics and safety-related findings.
Results: As of February 2018, 872 patients with C1-INH-HAE type I/II were enrolled, of whom 100 (11.5%) 
were ≥ 65 years old. Significant differences between elderly versus younger patients, respectively, were noted for 
median age at symptom onset (17.0 vs 12.0 years), age at diagnosis (41.0 vs 19.4 years), and delay between symptom 
onset and diagnosis (23.9 vs 4.8 years) (P ≤ 0.0001 for all). Median age at diagnosis was significantly higher in elderly 
patients regardless of family history (P < 0.0001). Throughout the study, icatibant was used to treat 6798 attacks in 
574 patients, with 63 elderly patients reporting 715 (10.5%) of the icatibant-treated attacks. No serious adverse events 
(SAEs) in elderly patients were judged to be possibly related to icatibant, whereas two younger patients reported 
three possibly related SAEs. Excluding off-label use and pregnancy (evaluated for regulatory purposes), the percent-
age of patients with at least one possibly/probably related AE was similar for elderly (2.0%) versus younger patients 
(2.7%). No deaths linked to icatibant treatment were identified. All related events in elderly patients were attributed to 
general disorders/administration site conditions, whereas related events in younger patients occurred across various 
system organ class designations.
Conclusions: Elderly patients with C1-INH-HAE were significantly older at diagnosis and had greater delay in 
diagnosis than younger patients. Elderly patients contributed to approximately 10% of the icatibant-treated attacks. 
Our analysis found similar AE rates (overall and possibly/probably related) in icatibant-treated elderly versus younger 
patients, despite the fact that elderly patients had significantly more comorbidities and were receiving a greater num-
ber of concomitant medications. Our analysis did not identify any new or unexpected safety concerns.
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Background
Hereditary angioedema with C1 inhibitor deficiency 
(C1-INH-HAE) is a rare, chronic disease caused by 
SERPING1 gene mutations [1]. Clinical manifestations 
include recurrent, unpredictable episodes of bradykinin-
mediated swelling in subcutaneous or submucosal tissues 
that are associated with a heavy burden of illness [2, 3]. 
Attacks can range from mild to severe and debilitating 
[4], negatively affecting patients’ ability to attend school, 
be productive at work, or participate in daily social activ-
ities [5].
Onset of symptoms typically begins within the first two 
decades of life (often by age 10–11  years), with inten-
sity of attacks worsening during puberty [6]. However, 
C1-INH-HAE attacks may occur at any age and recur 
throughout a patient’s lifetime [7, 8]. As such, treat-
ment of acute attacks is a lifelong necessity and can pose 
unique challenges for elderly patients. Presence of age-
related pharmacokinetic and pharmacodynamic changes, 
coupled with the high likelihood of comorbid conditions 
for which multiple medications are required, underscores 
the importance of monitoring the safe use of medication 
in this population [9]. To date, publications focused on 
managing C1-INH-HAE attacks in elderly patients are 
scarce. One observational registry study of 27 patients 
receiving an intravenously administered, plasma-derived 
C1-INH concentrate for the management of acute attacks 
demonstrated safe use in patients aged ≥ 65 years [10].
Icatibant, a subcutaneously administered antagonist 
of the bradykinin  B2 receptor, has demonstrated efficacy 
and safety for the treatment of acute attacks in adults 
with HAE type I/II in three Phase 3 randomized, double-
blind studies [11, 12]. However, mean patient age was 
< 65  years in all three trials [11, 12]. Although systemic 
exposure of icatibant has been shown to be increased in 
elderly patients, no effects on safety have been identified 
in this population [13].
The Icatibant Outcome Survey (IOS) is an ongoing 
international, prospective, observational drug registry 
study (NCT01034969) designed to monitor real-world 
safety and effectiveness of icatibant. Patients who are 
currently receiving, or are candidates for, treatment 
with icatibant are eligible to participate. Here, we com-
pare patient characteristics and safety-related findings in 
elderly versus younger patients with C1-INH-HAE type 
I/II enrolled in the IOS.
Methods
Study design
Data for this analysis were collected from July 2009 
through February 28, 2018, across 59 sites in 13 coun-
tries. The IOS study is conducted in compliance with the 
Declaration of Helsinki and the International Conference 
on Harmonisation Good Clinical Practice guidelines. 
Approvals were received from local ethics committees 
and/or health authorities, and patients provided written 
informed consent to participate.
Study design is presented in detail elsewhere [14]. 
Briefly, patient data were recorded via electronic forms 
by physicians at baseline and during follow-up visits 
(occurring approximately every 6  months), including 
frequency and severity of icatibant-treated attacks since 
the previous visit, safety/tolerability issues with icatibant 
treatment, presence of comorbid conditions and use of 
concomitant medications.
Adverse event‑related outcome measures
Adverse events (AEs) were assessed by frequency of 
occurrence, relationship to icatibant (possibly/prob-
ably/not related), and seriousness and severity (mild/
moderate/severe). AEs classified as “possibly related to 
treatment” were those that occurred within a reason-
able time sequence following administration of icati-
bant and are biologically plausible. Alternatively, the AE 
could be explained by concurrent disease or other drugs/
chemicals. AEs classified as “probably related to treat-
ment” were those that occurred within a reasonable time 
sequence following administration of icatibant, are bio-
logically plausible, and are unlikely to occur as a result of 
concurrent disease or other drugs/chemicals.
AEs were categorized in accordance with the Medical 
Dictionary for Regulatory Activities system organ class 
and preferred term, and analyzed by the proportions of 
occurrence (percentage of patients reporting an event). 
For reporting seriousness/relationship of AEs to icati-
bant, each patient was counted only once, and only the 
highest seriousness/relationship category was reported 
for that patient.
Statistical analysis
Descriptive analyses were conducted in younger patients 
(defined as ages < 65  years) versus elderly patients 
(≥ 65 years). Age at the time of data extract was used to 
define the age subgroups. For patients who discontinued 
early or died, age at discontinuation or death was used. 
Differences between age groups were evaluated using the 
Wilcoxon test for baseline characteristics; the Fisher test 
for possibly/probably related AEs and individual com-
parisons of mild, moderate, and severe AEs; and the Chi 
square test for individual comparisons of serious and 
non-serious AEs. Due to the observational nature of the 
registry, all analyses were considered exploratory; P-val-
ues were interpreted descriptively.
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Results
Baseline demographics and disease characteristics
As of February 28, 2018, 872 patients with C1-INH-HAE 
type I/II were enrolled in the IOS (Table  1). Significant 
differences between elderly versus younger patients, 
respectively, were noted for age at symptom onset 
(median 17.0 vs 12.0 years, P = 0.0001), age at diagnosis 
(median 41.0 vs 19.4 years, P < 0.0001), and delay between 
symptom onset and diagnosis (median 23.9 vs 4.8 years, 
P < 0.0001 [Table 1]). When evaluated in relation to fam-
ily history, median age at diagnosis was significantly 
higher in elderly than in younger patients, regardless 
of presence or absence of a family history (P < 0.0001, 
Fig.  1a). Whereas delay in diagnosis was significantly 
higher in elderly versus younger patients with a family 
history (23.9  vs 3.5  years, respectively, P < 0.0001); the 
Table 1 Baseline characteristics
C1-INH-HAE hereditary angioedema with C1 inhibitor deficiency, Q quartile
a Attacks with severity/location data included; attacks with “missing” or “unknown” severity/location excluded
Characteristics Elderly (≥ 65 years) Younger (< 65 years) Overall P‑value 
(elderly vs 
younger)
Patients, n (%) 100 (11.5) 772 (88.5) 872 (100)
 Type I 89 (89.0) 717 (92.9) 806 (92.4)
 Type II 11 (11.0) 55 (7.1) 66 (7.6) 0.1680
Sex
 Female, n (%) 51 (51.0) 471 (61.0) 522 (59.9) 0.0547
Age at enrollment (years)
 Median (Q1, Q3) 67.9 (63.8, 70.9) 36.8 (27.0, 47.3) 39.5 (27.9, 51.8) < 0.0001
Age at symptom onset (years)
 Median (Q1, Q3) 17.0 (7.0, 25.0) 12.0 (5.0, 18.0) 12.0 (5.0, 19.0) 0.0001
Age at diagnosis (years)
 Median (Q1, Q3) 41.0 (30.8, 59.0) 19.4 (11.4, 30.2) 21.1 (13.1, 33.8) < 0.0001
Delay in diagnosis, (years)
 Median (Q1, Q3) 23.9 (5.9, 37.2) 4.8 (0.21, 15.7) 6.1 (0.3, 17.5) < 0.0001
Family history of C1-INH-HAE, n, %
 Yes 71 (71.0) 565 (73.2) 636 (72.9)
 No 11 (11.0) 100 (13.0) 111 (12.7)
 Unknown 7 (7.0) 50 (6.5) 57 (6.5)
 Missing 11 (11.0) 57 (7.4) 68 (7.8) 0.6051
Attack severity, n (%)
 Number of  attacksa 581 5378 5959
 Very mild 11 (1.9) 18 (0.3) 29 (0.5)
 Mild 51 (8.8) 546 (10.2) 597 (10.0)
 Moderate 227 (39.1) 2202 (40.9) 2429 (40.8)
 Severe 219 (37.7) 1941 (36.1) 2160 (36.2)
 Very severe 73 (12.6) 671 (12.5) 744 (12.5)
  Very mild, mild, moderate vs severe/very severe 0.4393
Attack location, n (%)
 Number of  attacksa 726 6016 6742
 Skin 323 (44.5) 2702 (44.9) 3025 (44.9) 0.958
 Abdomen 369 (50.8) 3510 (58.3) 3879 (57.5) 0.438
 Larynx 38 (5.2) 293 (4.9) 331 (4.9)
 Other 70 (9.6) 216 (3.6) 286 (4.2)
Use of long-term prophylaxis, n (%) 2 (3.2) 8 (2.0) – 0.6329
Number of cardiovascular medications, per patient
 Number of patients 49 66 115
 Median (Q1, Q3) 2.0 (1.0, 3.0) 1.0 (1.0, 2.0) 1.0 (1.0, 2.0) 0.0019
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difference between age groups was not significant in the 
absence of a family history (10.2 vs 9.1 years, P = 0.2954; 
Fig. 1b).
Of attacks with available severity data, there was no 
difference between groups (P = 0.4393) when compar-
ing very mild/mild/moderate attacks versus severe/very 
severe attacks (Table  1). Attacks at a single site versus 
multiple sites comprised the majority of attacks in both 
the elderly and younger groups (elderly, 653/726 attacks 
[89.9%]; younger, 5339/6016 attacks [88.7%]) and there 
was no significant difference in attack location (Table 1).
Comorbid conditions and their treatment
Elderly patients were significantly more likely than 
younger patients to have multiple comorbidities, both at 
baseline (IOS entry; 52.0% vs 11.1%, P < 0.0001) and dur-
ing the follow-up period (26.0% vs 11.5%, P = 0.0002). For 
example, elderly patients were significantly more likely 
to have hypertension, ischemic heart disease, heart fail-
ure, stroke/transient ischemic attack, bleeding disorders, 
gastrointestinal disorders, diabetes, pulmonary disease, 
or renal-urogenital disorders at baseline, and hyperten-
sion, bleeding disorders, diabetes, and hepatic disor-
ders during the follow-up period (Tables 2, 3). Similarly, 
elderly patients received a greater number of concomi-
tant medications for cardiovascular/cerebrovascular con-
ditions, both at baseline (median 2.0 vs 1.0 medications 
per patient, P = 0.0019; Table  1) and during the follow-
up period (median 2.0 vs 1.0 medications per patient, 
P = 0.1238).
AEs related to icatibant treatment
During the time covered by this analysis, icatibant was 
used to treat 6798 attacks in 574 patients, with 715 
icatibant-treated attacks reported by 63 (63.0%) elderly 
patients. Elderly and younger patients were similarly 
likely to have at least one treated attack (63.0% vs 66.2%, 
P = 0.527).
A similar percentage of elderly and younger patients 
experienced at least one AE possibly or probably related 
Fig. 1 a Age at diagnosis in elderly and younger patients, with and without a family history and b delay in diagnosis in elderly and younger 
patients, with and without a family  historya. The horizontal line inside each box indicates the median, the lower and upper borders of each box 
indicate the first and third quartiles, and the lowest and highest horizontal lines outside the box indicate the minimum and maximum value.  
aA total of 113 patients with a family history had a negative delay in diagnosis (wherein diagnosis occurred before onset of symptoms, based on 
confirmatory laboratory testing); younger, n = 108; elderly, n = 5. Likewise, a total of five patients with no family history had a negative delay in 
diagnosis, all in the younger group
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Elderly (≥ 65 years) Younger (< 65 years) P Elderly (≥ 65 years) Younger (< 65 years) P
Bleeding 4 (4.0) 5 (0.6) 0.0130 4 (4.0) 5 (0.6) 0.0130
Cardiovascular/ 
cerebrovascular
50 (50) 69 (8.9)  < 0.0001 26 (26.0) 49 (6.3) <0.0001
Diabetes 11 (11.0) 17 (2.2) 0.0001 6 (6.0) 8 (1.0) 0.0027
Gastrointestinal 11 (11.0) 19 (2.5) 0.0002 7 (7.0) 24 (3.1) 0.0757
Hepatic 1 (1.0) 0 (0.0) 0.1147 2 (2.0) 1 (0.1) 0.0362
Immunological 2 (2.0) 25 (3.2) 0.7592 2 (2.0) 36 (4.7) 0.3008
Infections 1 (1.0) 8 (1.0) 1.0000 4 (4.0) 25 (3.2) 0.5650
Neoplasia 3 (3.0) 6 (0.08) 0.0735 0 (0.0) 2 (0.3) 1.0000
Neurological 1 (1.0) 9 (1.2) 1.0000 3 (3.0) 9 (1.2) 0.1498
Osteoarticular 1 (1.0) 7 (0.9) 1.0000 2 (2.0) 17 (2.2) 1.0000
Psychiatric 7 (7.0) 23 (3.0) 0.0706 6 (6.0) 25 (3.2) 0.1549
Pulmonary 7 (7.0) 11 (1.4) 0.0023 2 (2.0) 10 (1.3) 0.6380
Renal/urogenital 4 (4.0) 5 (0.6) 0.0130 3 (3.0) 6 (0.8) 0.0735




Elderly (≥ 65 years) Younger (< 65 years) P Elderly (≥ 65 years) Younger (< 65 years) P
Hypertension 48 (51.6) 64 (9.0) < 0.0001 13 (18.1) 27 (5.3)  0.0004
Angina 2 (2.2) 4 (0.6)  0.1435 0 (0.0) 1 (0.2)  1.0000
Ischemic heart 
disease
5 (5.4) 5 (0.7)  0.0028 0 (0.0) 2 (0.4)  1.0000
Heart failure 2 (2.2) 1 (0.1)  0.0363 1 (1.4) 0 (0.0)  0.1248
Stroke/transient 
ischemic attack
6 (6.5) 5 (0.7)  0.0006 1 (1.4) 3 (0.6)  0.4147
Table 4 Overall summary of AEs
AE adverse event
Elderly (≥ 65 years) Younger (< 65 years)
Patients (n = 100) Events Patients (n = 772) Events
Total AEs, n (%) 28 (28.0) 86 (100.0) 164 (21.2) 374 (100.0)
Occurrence of ≥ 1 icatibant-related AE, n (%) 2 (2.0) 19 (22.1) 21 (2.7) 68 (18.2)
AEs by relationship to icatibant use, n (%)
 Not recorded 0 (0.0) 0 (0.0) 11 (1.4) 28 (7.5)
 Not related 26 (26.0) 67 (77.9) 132 (17.1) 278 (74.3)
 Possibly related 0 (0.0) 0 (0.0) 5 (0.6) 34 (9.1)
 Probably related 2 (2.0) 19 (22.1) 16 (2.1) 34 (9.1)
Icatibant-related AEs by seriousness, n (%)
 Serious 0 (0.0) 0 (0.0) 2 (0.3) 3 (4.4)
 Not serious 2 (2.0) 19 (100.0) 19 (2.5) 65 (95.6)
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to icatibant (2.0% vs 2.7%; Table  4). No serious AEs 
(SAEs) occurring in elderly patients were judged to 
be possibly related to icatibant, whereas two younger 
patients reported three possibly related SAEs; one patient 
reporting gastritis (n = 1) and reflux esophagitis (n = 1), 
the other patient reporting angioedema crisis (n = 1).
The occurrence of mild and moderate AEs was similar 
between elderly and younger patients (P = 0.2170 and 
P = 0.2666, respectively). During the study, there were no 
deaths linked to treatment with icatibant.
A total of eight younger patients experiencing AEs had 
an older family member with C1-INH-HAE, however 
only two of these younger patients had an older fam-
ily member (their father) who also experienced AEs. No 
patterns were found in the type of AEs experienced by 
related patients.
Table 5 AEs possibly/probably related to icatibant, by system organ class and preferred  terma
a Excludes AEs related to off-label use and pregnancy; AE adverse event
Patients Elderly (≥ 65 years) 
(n = 100)
Younger (< 65 years) 
(n = 772)
Overall (n = 872)
Any AE n (%) 2 (2.0) 21 (2.7) 23 (2.6)
General disorders and administration site conditions 2 (2.0) 15 (1.9) 17 (1.9)
 Injection site erythema 1 (1.0) 9 (1.2) 10 (1.1)
 Pain 0 (0.0) 3 (0.4) 3 (0.3)
 Application site erythema 0 (0.0) 2 (0.3) 2 (0.2)
 Application site pain 0 (0.0) 2 (0.3) 2 (0.2)
 Infusion site pain 1 (1.0) 1 (0.1) 2 (0.2)
 Drug ineffective 0 (0.0) 1 (0.1) 1 (0.1)
 Infusion site erythema 1 (1.0) 0 (0.0) 1 (0.1)
 Injection site pain 1 (1.0) 0 (0.0) 1 (0.1)
 Injection site hemorrhage 0 (0.0) 1 (0.1) 1 (0.1)
 Localized edema 0 (0.0) 1 (0.1) 1 (0.1)
 Non-cardiac chest pain 0 (0.0) 1 (0.1) 1 (0.1)
 Edema 0 (0.0) 1 (0.1) 1 (0.1)
 Therapeutic product ineffective 0 (0.0) 1 (0.1) 1 (0.1)
 Infusion site urticaria 1 (1.0) 0 (0.0) 1 (0.1)
 Administration site reaction 1 (1.0) 0 (0.0) 1 (0.1)
 Asthenia 0 (0.0) 1 (0.1) 1 (0.1)
Vascular disorders 0 (0.0) 3 (0.4) 3 (0.3)
 Hyperemia 0 (0.0) 2 (0.3) 2 (0.2)
 Hot flush 0 (0.0) 1 (0.1) 1 (0.1)
Skin and subcutaneous tissue disorders 0 (0.0) 3 (0.4) 3 (0.3)
 Skin reaction 0 (0.0) 2 (0.3) 2 (0.2)
 Angioedema 0 (0.0) 1 (0.1) 1 (0.1)
Gastrointestinal disorders 0 (0.0) 4 (0.5) 4 (0.5)
 Nausea 0 (0.0) 2 (0.3) 2 (0.2)
 Abdominal distension 0 (0.0) 1 (0.1) 1 (0.1)
 Abdominal pain upper 0 (0.0) 1 (0.1) 1 (0.1)
 Reflux esophagitis 0 (0.0) 1 (0.1) 1 (0.1)
 Hiatus hernia 0 (0.0) 1 (0.1) 1 (0.1)
 Gastritis 0 (0.0) 1 (0.1) 1 (0.1)
Nervous system disorders 0 (0.0) 1 (0.1) 1 (0.1)
 Post-herpetic neuralgia 0 (0.0) 1 (0.1) 1 (0.1)
Investigations 0 (0.0) 1 (0.1) 1 (0.1)
 Blood pressure decreased 0 (0.0) 1 (0.1) 1 (0.1)
Infections and infestations 0 (0.0) 1 (0.1) 1 (0.1)
 Herpes zoster 0 (0.0) 1 (0.1) 1 (0.1)
Psychiatric disorders 0 (0.0) 1 (0.1) 1 (0.1)
 Depression 0 (0.0) 1 (0.1) 1 (0.1)
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Icatibant‑related AEs by system organ class
Excluding off-label use and pregnancy-related AEs 
(evaluated for regulatory purposes), all related events 
in elderly patients were attributed to general disorders/
administration site conditions, whereas treatment-
related events in younger patients occurred across vari-
ous system organ classes, including general disorders/
administration site conditions, vascular disorders, skin/
subcutaneous tissue disorders, gastrointestinal disorders, 
nervous system disorders, and others (Table 5).
Discussion and conclusions
To our knowledge, this is the first analysis that compares 
patient characteristics and safety and tolerability of icati-
bant in elderly versus younger patients with C1-INH-
HAE. Findings from our analysis revealed a significantly 
older age at diagnosis in elderly versus younger patients 
with C1-INH-HAE, regardless of family history. Inter-
estingly, delay in diagnosis was significantly longer in 
elderly versus younger patients in the presence of a posi-
tive family history, whereas the delay was similar for both 
age groups in the absence of a family history. This may 
have occurred due to the substantially larger number of 
younger patients with a positive family history (prompt-
ing earlier diagnosis), as well as better diagnostic work-
up in families in current clinical practice. The delay in 
elderly patients with a family history may also be caused 
by the fact that their relatives from previous generations 
may have given up seeking medical advice for their con-
dition and were living with symptoms, having lacked a 
formal diagnosis or effective C1-INH-HAE treatments in 
their own youth.
Our analysis did not reveal any new or unexpected 
safety concerns. Despite the fact that elderly patients had 
significantly more comorbidities and were receiving a 
greater number of concomitant medications, the occur-
rence of icatibant-related AEs was similar in the treated 
elderly versus younger population, with no significant 
differences noted between groups with regard to seri-
ousness or severity of AEs. These findings correlate with 
those previously reported in an observational drug reg-
istry study by Bygum et  al., who found no unexpected 
safety concerns in older versus younger patients treated 
with an intravenously administered, plasma-derived 
C1-INH in a real-world setting [10]. Additionally, no 
trends were noted with regard to the type of AEs expe-
rienced by younger patients who were related to an older 
patient enrolled in the IOS.
Our study had several limitations, including an uncon-
trolled clinical environment inherent in an observational 
study design; description of AEs relied heavily on patient 
recall. Additionally, substantially fewer elderly than 
younger patients were enrolled.
Despite the limitations, our real-world analysis pro-
vides valuable insight with regard to clinical charac-
teristics of elderly patients with C1-INH-HAE and the 
safety of treating acute attacks with icatibant in this 
patient population.
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